Zeinab Dalloul | Cancer Genomics Computational Studies | Research Excellence Award

Published on by Computational Biologists

Research Excellence Award

Zeinab Dalloul
Algentics

Zeinab Dalloul
Affiliation Algentics
Country Canada
Scopus ID 57191171462
Documents 14
Citations 110
h-index 5
Subject Area Cancer Genomics Computational Studies
Event Computational Biologists Awards

Zeinab Dalloul is affiliated with Algentics in Canada and is represented in the supplied scholarly records within the field of cancer genomics computational studies. The supplied Scopus record reports 14 documents, 110 citations, and an h-index of 5. These indicators provide quantitative information about the indexed scholarly record and can be considered alongside publication content, subject relevance, and other evidence in an academic recognition review. [1]

Abstract

Zeinab Dalloul is affiliated with Algentics in Canada and is represented in the supplied scholarly records as a researcher working within cancer genomics computational studies. Her indexed profile reports 14 documents, 110 citations, and an h-index of 5. These bibliometric indicators provide measurable information about publication activity and citation reach within indexed literature. Her research area connects computational approaches with cancer genomics, a field that integrates biological data, computational analysis, and genomic interpretation to investigate cancer-related molecular characteristics. The Research Excellence Award profile considers her documented research record, subject alignment, scholarly output, and measurable citation indicators in relation to computational biology. [1]

Keywords

Cancer Genomics, Computational Biology, Genomic Analysis, Bioinformatics, Cancer Research, Computational Genomics, Biomedical Data Analysis, Research Excellence. [1]

Introduction

Computational cancer genomics applies computational and bioinformatic methods to genomic and molecular datasets generated through cancer research. Such approaches support the analysis of complex biological information and the interpretation of genomic variation, molecular patterns, and disease-associated datasets. Dalloul’s supplied researcher profile is situated within this interdisciplinary subject area and is documented through an indexed Scopus author record. [1]

Research Profile

Dalloul’s research profile is associated with cancer genomics computational studies, placing the supplied record at the intersection of genomics, computational biology, and biomedical research. The supplied bibliometric record identifies 14 indexed documents and 110 citations, with an h-index of 5. These measures describe publication and citation activity but do not independently establish the scientific content, methodology, or significance of individual studies. [1]

Research Contributions

Within cancer genomics computational studies, research contributions may involve the organization, analysis, and interpretation of genomic datasets using computational methods. Dalloul’s documented subject area indicates relevance to this research domain, while the available publication and citation indicators provide evidence of an indexed scholarly record. Specific methodological contributions should be assessed from individual publications and their full scientific content. [1]

Publications

The supplied Scopus information records 14 documents associated with Zeinab Dalloul’s author profile. This document count represents indexed scholarly output within the referenced database and should be interpreted according to database coverage and author-profile attribution. Individual publication titles, journals, publication dates, authorship positions, and article-level identifiers were not supplied and therefore are not reproduced here. [1]

Research Impact

The supplied bibliometric record reports 110 citations and an h-index of 5. Citation counts provide one quantitative measure of how frequently indexed publications have been cited, while the h-index combines publication and citation information into a single indicator. Such metrics can vary according to database coverage, field characteristics, publication age, and author disambiguation, so they are most appropriately considered alongside qualitative evidence. [1]

Award Suitability

The supplied profile contains an identified affiliation with Algentics, a defined subject area in cancer genomics computational studies, an indexed publication record, and measurable citation indicators. These elements provide documented information that can be considered within a research-recognition review associated with the Computational Biologists Awards. Final recognition remains subject to the award program’s applicable eligibility, evaluation, and verification procedures. [3]

Conclusion

Zeinab Dalloul’s supplied academic profile describes a researcher affiliated with Algentics in Canada and associated with cancer genomics computational studies. The available Scopus information records 14 documents, 110 citations, and an h-index of 5. These data provide a concise bibliometric description of the indexed research record, while detailed assessment of scientific contributions requires examination of the underlying publications and supporting scholarly evidence. [1] [2]

References

  1. Elsevier. (n.d.). Scopus author details: Zeinab Dalloul, Author ID 57191171462. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57191171462
  2. Review article. (2025.) Leveraging liquid biopsy to uncover resistance mechanisms and guide personalized immunotherapy.
    https://doi.org/10.1016/j.tranon.2025.102445
  3. Computational Biologists Awards. (2026. )  Computational Biologists Awards.
    https://computationalbiologists.com/

Jin-Ji Yang | Pulmonary oncology | Personalized Medicine Innovation

Published on by Computational Biologists

Personalized Medicine Innovation

Jin-Ji Yang
Guangdong Provincial People’s Hospital

Jin-Ji Yang
Affiliation Guangdong Provincial People’s Hospital
Country China
Scopus ID 57543111300
Documents 1
Citations 2
h-index 1
Subject Area Pulmonary oncology
Event Computational Biologists Awards
ORCID 0000-0002-8498-0119

Jin-Ji Yang is affiliated with Guangdong Provincial People’s Hospital in China and is identified in Scopus under Author ID 57543111300. The documented research subject area is pulmonary oncology, providing a clinical and biomedical context for considering personalized medicine and computational approaches. The available bibliometric record currently lists one document, two citations, and an h-index of one. [1] The researcher’s ORCID identifier provides an additional persistent scholarly identity record. [2]

Abstract

Jin-Ji Yang is a researcher affiliated with Guangdong Provincial People’s Hospital whose documented subject area is pulmonary oncology. The available Scopus record identifies one scholarly document, two citations, and an h-index of one. These metrics provide a limited quantitative snapshot of the researcher’s indexed scholarly output and citation activity. [1] The research profile is additionally associated with ORCID identifier 0000-0002-8498-0119, supporting persistent identification across scholarly systems. [2] Within personalized medicine, pulmonary oncology represents a field where clinical information, molecular evidence, and computational analysis can contribute to individualized research frameworks. This article summarizes the documented profile and its relevance to the Computational Biologists Awards.

Keywords

Personalized Medicine; Pulmonary Oncology; Computational Biology; Biomedical Research; Clinical Informatics; Oncology; Precision Medicine; Guangdong Provincial People’s Hospital; Research Impact; Computational Biologists Awards.

Introduction

Personalized medicine integrates patient-specific biological and clinical information to support more individualized approaches to research and healthcare. Computational biology contributes analytical methods for interpreting complex biomedical datasets. Within pulmonary oncology, these approaches can support investigation of disease characteristics and treatment-related questions. Yang’s documented subject area places the researcher within this interdisciplinary context. [1]

Research Profile

Jin-Ji Yang is affiliated with Guangdong Provincial People’s Hospital in China, with pulmonary oncology identified as the recorded subject area. The Scopus author record currently contains one document and two citations, with an h-index of one. [1] ORCID registration provides a persistent identifier that can help distinguish the researcher within scholarly communication systems. [2]

Research Contributions

The documented research area of pulmonary oncology provides a basis for examining questions at the intersection of oncology, clinical research, and personalized medicine. Computational approaches in such settings may involve structured analysis of biological or clinical information. The available record, however, does not provide sufficient evidence to attribute specific computational methods or broader contributions beyond the indexed subject classification. [1]

Publications

The available Scopus author information records one document for Jin-Ji Yang. [1] Because the supplied bibliographic information does not include the publication title, journal, publication year, or DOI, those details are not inferred here. The indexed document count should therefore be understood as a bibliometric record rather than a complete description of the researcher’s entire scholarly output.

Research Impact

The supplied Scopus metrics report two citations and an h-index of one for the identified author record. [1] These indicators describe indexed citation activity at the time represented by the record and should not be interpreted independently as a comprehensive measure of research influence. Citation counts can vary between databases, disciplines, publication periods, and indexing practices, while ORCID provides identification rather than an impact metric. [2]

Award Suitability

For an award review focused on personalized medicine innovation, the documented affiliation and pulmonary oncology subject area provide relevant professional context. [1] The available record can support consideration of subject-area alignment, while a complete assessment would ordinarily require the specific publication, research methods, documented findings, and evidence of innovation supplied in an application. The Computational Biologists Awards website provides the relevant award context. [3]

Conclusion

Jin-Ji Yang’s documented scholarly profile connects Guangdong Provincial People’s Hospital with pulmonary oncology and a research context relevant to personalized medicine. The current indexed record reports one document, two citations, and an h-index of one. [1] ORCID further establishes a persistent researcher identifier. [2] Additional publications, methodological details, and research outcomes would provide broader evidence for evaluating the scope of computational or personalized-medicine contributions.

References

  1. Elsevier. (n.d.). Scopus author details: Jin-Ji Yang, Author ID 57543111300. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57543111300
  2. ORCID. (n.d.). Jin-Ji Yang — ORCID record. ORCID.
    https://orcid.org/0000-0002-8498-0119
  3. Computational Biologists Awards. (2026.)  Computational Biologists Awards.
    https://computationalbiologists.com/
  4. Research Article (2021. ) Clinicopathological features and resistance mechanisms in HIP1-ALK-rearranged lung cancer: A multicenter study.
    https://doi.org/10.1002/gcc.23005

Weiling He | Cancer Genomics Computational Studies | Best Researcher Award

Published on by Computational Biologists

Prof. Weiling He | Cancer Genomics Computational Studies | Best Researcher Award

Professor at Xiamen University, China

Dr. Weiling He is a leading figure in precision oncology, serving as Chief Physician, Professor, Doctoral and Postdoctoral Supervisor, and President of Xiang’an Hospital at Xiamen University. He is widely recognized for his contributions to cancer treatment, particularly in the domains of tumor microenvironments and drug resistance. Honored with the National Natural Science Foundation of China’s Excellent Young Scientist Fund and recognized as a Distinguished Young Medical Talent of Guangdong Province, Dr. He has established himself as a trailblazer in translational medical research. His prolific output includes over 50 SCI-indexed publications and six granted patents, underscoring his influence in both academia and clinical application.

Profile

Scopus

Education

Dr. He holds both an MD and a PhD, equipping him with a robust foundation for navigating the complex landscape of cancer research and treatment. His academic journey reflects a commitment to scientific excellence and multidisciplinary learning, enabling him to bridge the gap between theoretical research and clinical practice. The integration of medicine and scientific inquiry during his training shaped his ongoing work in precision medicine, translational oncology, and systems biology.

Experience

With a career marked by leadership and innovation, Dr. He currently serves as the President of Xiang’an Hospital at Xiamen University. He has led more than 20 research projects at the national and provincial levels, including prestigious programs under the National Key R&D Initiative and the National Natural Science Foundation of China. Dr. He has also contributed extensively to industry-academia collaboration, participating in strategic projects like the Guangdong Soft Science Program and the Guangzhou Future Industry Initiative. His academic affiliations include leadership roles in over ten national medical associations, reflecting a deep engagement with both clinical and academic ecosystems.

Research Interest

Dr. He’s research focuses on unraveling the mechanisms of tumor drug resistance, exploring metastasis pathways, and analyzing the tumor microenvironment. He is particularly interested in precision interventional therapy and the development of biomaterials and microfluidic technologies for real-time monitoring and treatment. His interdisciplinary approach combines oncology, engineering, and systems biology to improve the outcomes of metastatic cancer therapies. Through collaborative research with institutions such as Sun Yat-sen University and Emory University, he advances new methodologies in clinical translation and integrative cancer treatment.

Award

Dr. Weiling He has received several distinguished honors throughout his career. Among them, the National Natural Science Foundation of China awarded him the Excellent Young Scientist Fund, recognizing his outstanding potential and research impact in oncology. In addition, he was named a Distinguished Young Medical Talent of Guangdong Province, affirming his influence on medical innovation and leadership. His work is frequently acknowledged in national and international forums, and he has played a pivotal role in advancing precision medicine initiatives across China.

Publication

Dr. He has authored more than 50 papers indexed in SCI journals, with several appearing in top-tier publications. Notable recent works include:

“Immune Microenvironment Remodeling in Colorectal Cancer,” Cancer Immunology Research, 2020 – cited 326 times.

“Dual Nanoparticle Delivery in Precision Oncology,” Advanced Science, 2021.

“Microfluidic Chips for Real-time Tumor Monitoring,” Nature Communications, 2022.

“Translational Biomaterials in Interventional Therapy,” Science Translational Medicine, 2023 (cover article).

“Integrated Oncology Systems for Drug Resistance,” Nature Cancer, 2023.

“Microsphere Technology for Metastatic Cancer,” Advanced Science, 2024.

“Tumor Sensitization Targets for Interventional Therapy,” Nature Communications, 2024.

These publications have garnered over 1000 citations in total, with multiple works recognized as “Highly Cited Papers” in their respective fields.

Conclusion

Dr. Weiling He’s exceptional academic record, impactful research, numerous high-impact publications, robust patent portfolio, and her pivotal role in the advancement of precision oncology mark her as a standout candidate for the Best Researcher Award. Her commitment to interdisciplinary innovation and translational impact makes her not only deserving of this honor but a role model for future generations in computational and medical biology.

Gayatri Iyer | Pharmacogenomics | Best Researcher Award

Published on by Computational Biologists

Dr. Gayatri Iyer | Pharmacogenomics | Best Researcher Award

Scientist III at Tata Institute for Genetics and Society, India

Dr. Gayatri R. Iyer is a leading clinical geneticist and molecular biologist specializing in genetic counseling and rare disease diagnostics. With over a decade of hands-on experience in both research and clinical genetics, she bridges molecular science with patient-centric healthcare. She currently serves as Scientist Grade II at the Tata Institute for Genetics and Society, where she develops cost-effective diagnostic solutions for complex genetic disorders. Certified at Level II by the Board of Genetic Counseling, India, and holding an INSPIRE fellowship from the Department of Science and Technology, her professional journey reflects excellence in research, diagnostics, and community outreach. Her multidisciplinary expertise and contributions make her a standout nominee in the field of translational genetics.

profile

google scholar

Education

Dr. Iyer’s academic foundation is built on a rigorous and multidisciplinary path. She earned her Ph.D. in Human Genetics from Kamineni Hospitals, affiliated with Osmania University, where she was a DST-INSPIRE Fellow (2016–2021). Her doctoral research focused on developing methylation-specific PCR assays for imprinting disorders, reflecting her dedication to translating molecular diagnostics into clinical practice. She completed her M.Sc. in Applied Genetics from The Oxford College of Science, Bangalore, with a gold medal for academic excellence (2012–2014), and secured second rank in her B.Sc. in Biotechnology from Birla College, Mumbai (2012). She has supplemented her academic training with a PG Certificate in Medical & Genetic Counseling and a diploma in Bioinformatics.

Experience

With progressive experience in clinical genetics, Dr. Iyer has held diverse roles across premier institutions. At the Tata Institute for Genetics and Society (2023–present), she focuses on developing diagnostic platforms for rare disorders such as imprinting syndromes and neuromuscular conditions. During her postdoctoral fellowship at IIT Bombay (2022–2023), she worked on subcellular proteomics and gut microbiome sequencing. At Kamineni Hospitals, Hyderabad (2015–2021), she evolved from a Junior to Senior Research Fellow and served as a senior genetic counselor, managing over 2,000 cases across specialties including pediatrics, oncology, and reproductive medicine. Her work at LifeCell International and Datar Genetics further solidified her position as an expert counselor and educator.

Research Interest

Dr. Iyer’s research is centered on rare genetic diseases, molecular diagnostics, pharmacogenomics, and genetic counseling. She is especially focused on developing accessible and cost-effective diagnostic tools for Indian and resource-limited populations. Her doctoral work on imprinting disorders was groundbreaking, contributing novel diagnostic pathways for syndromes like Prader-Willi and Angelman. She is equally invested in epigenetics, next-generation sequencing, and microarray-based diagnostics. Her translational approach ensures that molecular insights are effectively integrated into patient care, family screening, and policy development. She continues to bridge the gap between lab-based discoveries and real-world clinical applications through genetic counseling and education.

Awards

Dr. Iyer’s contributions have been consistently recognized at national and international levels. She is the recipient of the DST Faculty Research Grant (2024–2029) and co-investigator on an ICMR CAR grant. Her global reputation was affirmed by receiving a $3,500 workshop grant and a travel grant from the International Prader-Willi Syndrome Organization. She was awarded the prestigious DST-INSPIRE Fellowship (2016–2021) and secured a travel grant to present her research at the Asia Pacific Prader-Willi Conference in Brisbane (2018). Her academic accolades include the Gold Medal in M.Sc. Applied Genetics and first rank in her Bioinformatics diploma. She also serves as Joint Secretary of the Executive Committee, Board of Genetic Counseling, India.

Publications

Dr. Iyer has contributed to over 15 peer-reviewed journal articles and book chapters. Selected impactful publications include:

Halder A, Iyer G, et al. (2023). Targeted proteomics distinguishes high and low grade meningioma tumors. Clin Proteomics, 20(1):41. [Cited by: 5]

Bajaj S, Iyer G, et al. (2022). Telegenetics diagnosis of Hunter syndrome during COVID-19. Int J Contemp Pediatr, 9:851–4. [Cited by: 2]

Iyer GR, et al. (2022). NGS in musculoskeletal disorders. J Orthop Surg Res, 17(1):76. [Cited by: 3]

Iyer GR, et al. (2021). Angelman syndrome phenotype with GABRG3. Ann Hum Genet, doi:10.1111/ahg.12449. [Cited by: 4]

Abbas NZ, Iyer GR, et al. (2020). Genotype-Phenotype correlation in pediatric neurology. Int J Health Clin Res, 3(5):67–73. [Cited by: 2]

Iyer G, et al. (2020). COVID-19 therapy driven by pharmacogenomics. AIJR Preprints. [Cited by: 7]

Iyer GR, et al. (2020). Host gene variants and COVID-19 progression. Front Genet, 11:861. [Cited by: 10]

Conclusion

Dr. Gayatri R. Iyer exemplifies the ethos of a best researcher through her unwavering commitment to bridging science and clinical application. Her pioneering work in low-cost diagnostic development for rare disorders, hands-on clinical counseling experience, interdisciplinary teaching, and highly cited publications affirm her exceptional contribution to medical genetics and public health. Her nomination for the Best Researcher Award is a recognition of her dedication, innovation, and leadership in translating genetic research into impactful health solutions.

Shuying FENG | Functional Genomics | Best Researcher Award

Published on by Computational Biologists

Prof. Shuying FENG | Functional Genomics | Best Researcher Award

Director at Henan University of Chinese Medicine, China.

Dr. Shuying Feng is a Professor, PhD, and Postdoctoral Supervisor at Henan University of Chinese Medicine, where he leads several key research centers focused on functional and special medical foods. A nationally recognized expert in traditional Chinese medicine, his work integrates nanotechnology, probiotic fermentation, gene editing, and the medical application of natural products. Dr. Shuying Feng has published over 100 papers (90+ SCI-indexed), holds 21 national invention patents, and has directed numerous national and provincial projects. He is also a distinguished academic leader, mentor, and recipient of multiple scientific and technological awards.

🎓 Academic Background :

Dr. Shuying Feng is a highly accomplished Professor and Doctoral/Postdoctoral Supervisor at Henan University of Chinese Medicine. Holding a PhD and serving as a leading scholar in his field, Dr. Shuying Feng is also a member of the Communist Party of China. He currently leads several prominent research institutions, including the Henan Engineering Research Center for Special Medical Foods of Traditional Chinese Medicine, and serves as Executive Director of the Institute of Functional Foods and Medicine-Food Homologous Research. His academic leadership has significantly influenced the advancement of traditional Chinese medicine and functional food research across Henan Province and beyond.

Profile:

Professional Experience:

Dr. Shuying Feng has extensive professional experience as a professor, researcher, and academic leader in the field of traditional Chinese medicine and functional foods. He currently serves as Director of multiple research centers, including the Henan Engineering Research Center for Special Medical Foods, and holds executive roles at key provincial and municipal laboratories. Over his career, he has led more than 30 national, provincial, and industry-funded research projects, secured significant research funding, and guided numerous graduate and postdoctoral researchers. His work has resulted in over 100 publications, 21 national patents, and wide-ranging contributions to both academic and industrial advancements in medical food innovation.

🔬 Research Interests:

Dr. Shuying Feng’s research spans several pioneering fields within biomedical science and traditional medicine. His primary areas of interest include the development of functional and special medical foods, the nanoization and probiotic fermentation enhancement of traditional Chinese medicine, gene editing and its applications in microalgae, and the medical applications of bee products. His multidisciplinary approach bridges ancient medicinal wisdom with cutting-edge biotechnology, driving innovation in both health and food sciences.

🏅 Honors & Recognition:

Dr. Shuying Feng has been recognized with numerous accolades, including the title of Distinguished Professor of Henan Province, High-Level Talent (Category C), Academic and Technical Leader by the Henan Department of Education, and Outstanding Young Backbone Teacher in Higher Education. At the city level, he has been named an Excellent Scientific and Technological Talent. These honors underscore his contributions to both academic excellence and public service in the field of medical science.

🏛️ Leadership & Roles:

Beyond his research and teaching, Dr. Feng holds influential roles in academic societies. He is Vice Chairman of the Tumor Cell Professional Committee of the Henan Cell Biology Society and a council member of both the Fermentation Research Committee under the World Federation of Chinese Medicine Societies and the Henan Biochemistry and Molecular Biology Society. These leadership positions highlight his commitment to collaborative scientific advancement and community engagement.

Publications:

  • Meng, Y., Si, Y., Guo, T., Sun, K., & Feng, S. (2025). Ethoxychelerythrine as a potential therapeutic strategy targets PI3K/AKT/mTOR induced mitochondrial apoptosis in the treatment of colorectal cancer. Scientific Reports.
    🔹 Citations: 1

  • Ji, C., Li, S., Hu, C., Yin, S., & Feng, S. (2024). Traditional Chinese medicine as a promising choice for future control of PEDV. (Journal name not specified).
    🔹 Citations: 0

  • Zhang, B., Wang, Q., Zhang, Y., Wang, B., & Feng, S. (2024). Treatment of insomnia with traditional Chinese medicine presents a promising prospect. (Journal name not specified).
    🔹 Citations: 0

  • Yang, Y., Li, S., Shi, W., Lu, B., & Feng, S. (2024). Pterostilbene suppresses the growth of esophageal squamous cell carcinoma by inhibiting glycolysis and PKM2/STAT3/c-MYC signaling pathway. International Immunopharmacology.
    🔹 Citations: 1

  • Wei, W., Guo, T., Fan, W., Ma, W., & Feng, S. (2024). Integrative analysis of metabolome and transcriptome provides new insights into functional components of Lilii Bulbus. Chinese Herbal Medicines.
    🔹 Citations: 5

Nazanin Zounemat-Kermani | Computational Systems Medicine | Best Researcher Award

Published on by Computational Biologists

Dr Nazanin Zounemat-Kermani | Computational Systems Medicine | Best Researcher Award

Dr. Nazanin Zounemat-Kermani is an accomplished biomedical data scientist whose research stands at the forefront of precision medicine, respiratory disease, and artificial intelligence. Currently serving as a Postdoctoral Research Associate at both the National Heart and Lung Institute (NHLI) and the Data Science Institute (DSI) at Imperial College London, she has earned international recognition for her leadership in multi-omics data integration and machine learning applications in health sciences.

Profile:

🎓 Educational Background:

Dr. Kermani’s academic journey reflects a rare interdisciplinary blend of computer science and biomedical research. She holds a PhD in Biomedicine from Imperial College London (2020), following dual master’s degrees in Artificial Intelligence from the University of Amsterdam (2011) and Machine Learning and Robotics from the University of Tehran (2004). Her academic roots trace back to a Bachelor of Engineering in Software Engineering from Ferdowsi University of Mashhad (2002).

💼 Professional Experience:

Since 2020, Dr. Kermani has worked as a Postdoctoral Research Associate at Imperial College London, after several years as a Research Assistant and PhD candidate in Zoltan Takats’ Lab. Her academic trajectory within one of the world’s top institutions reflects both her scientific rigor and leadership capabilities.

🎓🤝 Academic Mentorship:

Dr. Nazanin Zounemat-Kermani is widely respected not only for her scientific contributions but also for her unwavering commitment to mentorship and academic leadership. Throughout her career, she has actively nurtured the growth of early-career scientists, postdoctoral researchers, and graduate students. As a senior member of interdisciplinary consortia such as AI-RESPIRE, PRISM, and U-BIOPRED, she has led cross-functional teams spanning clinical science, data engineering, and machine learning—mentoring junior colleagues in both technical development and scientific publishing. Her leadership style is inclusive and empowering, emphasizing hands-on guidance in areas such as statistical modeling, research communication, and responsible data science.

🏆 Awards and Honors:

Dr. Kermani has received numerous accolades, including the MSACL Young Investigator Award (2016), Scholar Awards from the American Thoracic Society (2022, 2023), and multiple research grants from prestigious bodies such as the UKRI, MRC, and EPSRC. She has also been invited to present her research by eminent scholars at institutions like Oxford University and Amsterdam UMC.

🌍 Global Projects and Leadership

Dr. Kermani has led and contributed to numerous high-impact international projects, including:

  • RASP-UK: She developed a robust data management platform supporting clinical and omics data integration for asthma research.

  • PIONEER: Co-led machine learning initiatives in prostate cancer, resulting in a key senior-author publication.

  • U-BIOPRED: Coordinated Europe’s largest severe asthma cohort study, publishing over 20 peer-reviewed articles and acting as corresponding author on influential multi-omics studies.

  • UK-Korea PRISM: Leads cross-national efforts in asthma pathophysiology using advanced analytics and single-cell data.

  • AI-RESPIRE: Heads AI model development for environmental and physiological time-series data, mentoring early-career researchers.

  • DeVENT and PROmics: Oversees analysis in critical care and deep learning integration in patient-reported outcomes.

📚 Publications:

  1. CC16 Confers Protection Against Influenza A Virus Infection in Human Airway Epithelium
    H. Kimura, N.Z. Kermani, N. Kimura, M.M. Siddiq, D. Francisco, I.M. Adcock, et al.
    American Journal of Respiratory and Critical Care Medicine, Vol. 211 (Abstracts), 2025.

  2. Distinct Single-Cell Transcriptional Profile in CD4⁺ T-Lymphocytes Among Obese Children With Asthma
    V. Tejwani, R. Wang, A. Villabona-Rueda, K. Suresh, T.D. Wu, I.M. Adcock, et al.
    American Journal of Physiology – Lung Cellular and Molecular Physiology, Vol. 328(3), 2025.

  3. Female Sex Hormones and the Oral Contraceptive Pill Modulate Asthma Severity Through GLUT-1
    A.C. Brown, O.R. Carroll, J.R. Mayall, N. Zounemat-Kermani, S.L.E. Vinzenz, et al.
    Mucosal Immunology, 2025.

  4. Neutrophilic Inflammation in Sputum or Blood Does Not Define a Clinically Distinct Asthma Phenotype in ATLANTIS
    P.J.M. Kuks, T.M. Kole, M. Kraft, S. Siddiqui, L.M. Fabbri, K.F. Rabe, A. Papi, et al.
    ERJ Open Research, Vol. 11(1), 2025.

  5. The Role of WNT5a and TGF‐β1 in Airway Remodelling and Severe Asthma
    T. Daud, S. Roberts, N. Zounemat-Kermani, M. Richardson, L.G. Heaney, et al.
    Allergy, 2025.

  6. Clinical Importance of Patient-Reported Outcome Measures in Severe Asthma: Results from U-BIOPRED
    R. Meys, F.M.E. Franssen, A.J. Van ‘t Hul, P.S. Bakke, M. Caruso, B. Dahlén, et al.
    Health and Quality of Life Outcomes, Vol. 22(1), Article 109, 2024.

  7. Radiomultiomics: Quantitative CT Clusters of Severe Asthma Associated With Multiomics
    N.Z. Kermani, K.F. Chung, G. Macis, G. Santini, F.A.A. Clemeno, A. Versi, K. Sun, et al.
    European Respiratory Journal, Vol. 64(5), 2024.

  8. S12 Association Between Disease Duration and FEV1 in Severe Asthma Phenotypes and Endotypes
    F. Yang, N. Zounemat-Kermani, P. Dixey, I.M. Adcock, C.I. Bloom, K.F. Chung
    Thorax, Vol. 79(Suppl 2), A15–A16, 2024.

  9. S120 Post-Hoc Analysis of Transcriptomic and Clinical Predictors of Remission in the ATLANTIS Cohort
    A.A. Kumar, T.M. Kole, M.C. Nawijn, K.F. Rabe, A. Papi, C. Brightling, D. Singh, et al.
    Thorax, Vol. 79(Suppl 2), A83–A84, 2024.

  10. Discovery and Validation of a Volatile Signature of Eosinophilic Airway Inflammation in Asthma
    R. Peltrini, R.L. Cordell, M. Wilde, S. Abuhelal, E. Quek, N. Zounemat-Kermani, et al.
    American Journal of Respiratory and Critical Care Medicine, Vol. 210(9), pp. 1101–1112, 2024.

  11. Cardiovascular Events in CML Patients Treated With Nilotinib: Validation of the HFA-ICOS Baseline Risk Score
    M. Andres, F. Fernando, S. Claudiani, N. Kermani, G. Ceccarelli, J. Apperley, et al.
    European Heart Journal, Vol. 45(Suppl 1), ehae666.3169, 2024.

  12. Scientific Business Abstracts
    F. Cooles, G. Vidal-Pedrola, N. Naamane, A. Pratt, B. Barron-Millar, et al.
    QJM: An International Journal of Medicine, Article hcae157, 2024.

  13. A Severe Asthma Phenotype of Excessive Airway Haemophilus influenzae Relative Abundance Associated With Sputum Neutrophilia
    A. Versi, A. Azim, F.X. Ivan, M.I. Abdel-Aziz, S. Bates, J. Riley, M. Uddin, et al.
    Clinical and Translational Medicine, Vol. 14(9), e70007, 2024.

  14. Host-Microbial Interactions Differ With Age of Asthma Onset
    A. Versi, A. Azim, F.X. Ivan, M.I. Abdel-Aziz, S. Bates, J. Riley, et al.
    European Respiratory Journal, 2024.

  15. Cardiovascular Events in CML Patients Treated With Nilotinib: Validation of the HFA-ICOS Baseline Risk Score
    F. Fernando, M.S. Andres, S. Claudiani, N.Z. Kermani, G. Ceccarelli, A.J. Innes, et al.
    Cardio-Oncology, Vol. 10(1), Article 42, 2024.

  16. Endotypes of Severe Neutrophilic and Eosinophilic Asthma From Multi-Omics Integration of U-BIOPRED Sputum Samples
    N.Z. Kermani, C.X. Li, A. Versi, Y. Badi, K. Sun, M.I. Abdel-Aziz, M. Bonatti, et al.
    Clinical and Translational Medicine, Vol. 14(7), e1771, 2024.

  17. IL-33 Induced Gene Expression in Activated Th2 Effector Cells Is Dependent on IL-1RL1 Haplotype and Asthma Status
    A.K.S. Jayalatha, M.E. Ketelaar, L. Hesse, Y.E. Badi, N. Zounemat-Kermani, et al.
    European Respiratory Journal, Vol. 63(6), 2024.

  18. Comparison of Asthma Phenotypes in Severe Asthma Cohorts (SARP, U-BIOPRED, ProAR and COREA) From Four Continents
    S.Y. Park, S. Fowler, D.E. Shaw, I.M. Adcock, A.R. Sousa, R. Djukanovic, et al.
    Allergy, Asthma & Immunology Research, Vol. 16(4), p. 338, 2024.

  19. Enose-Derived Response Clusters in Severe Asthmatics Treated With Anti-IL5/5R Biologics
    P. Dixey, N. Zounemat-Kermani, K. Raby, P.K. Bhavsar, K.F. Chung
    B16. Novel Insights Into Asthma Pathogenesis, A3013, 2024.

  20. Association of CC16 Expression in the Airways With Signature Expression of Multi-Omics Data
    H. Kimura, N.Z. Kermani, I.M. Adcock, K.F. Chung, M. Kraft
    D91. Bridging the Gap: Translational Studies in ARDS, Pneumonia, and Sepsis, 2024.